OncoMatch/Clinical Trials/NCT06929286
A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)
Is NCT06929286 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Nadofaragene Firadenovec and Gemcitabine for non-muscle invasive bladder cancer.
Treatment: Nadofaragene Firadenovec · Gemcitabine · Docetaxel — The purpose of this study is to compare the effectiveness of different FDA-approved/NCCN-recommended drug treatments for NMIBC. In particular, the FDA-approved drug nadofaragene firadenovec will be compared to usual care with other NCCN-recommended standard treatments for NMIBC (gemcitabine with or without docetaxel, mitomycin, re-treatment with BCG, or pembrolizumab).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Urothelial Carcinoma
Disease stage
Required: Stage TIS
Grade: high
Demographics
Prior therapy
Must have received: BCG — induction
One or more prior induction course of BCG at any point in time and judgment by the treating urologist that BCG has failed
Must have received: intravesical therapy or systemic therapy for NMIBC — induction or maintenance
In the previous 12 months, receipt of at least one instillation of any intravesical agent (induction or maintenance) or one administration of systemic therapy for NMIBC treatment
Cannot have received: nadofaragene firadenovec (nadofaragene firadenovec)
Prior exposure to nadofaragene firadenovec
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06929286 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior nadofaragene firadenovec disqualifies patients from enrollment.
What disease stage is eligible?
Stage TIS is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages